Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
|Title||Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.|
|Publication Type||Journal Article|
|Year of Publication||2009|
|Authors||Feusner, JD, Kerwin L, Saxena S, Bystritsky A|
|Keywords||Adult, Anxiety Disorders, Excitatory Amino Acid Antagonists, Female, Humans, Male, Memantine, Middle Aged, Obsessive-Compulsive Disorder, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Young Adult|
A substantial proportion of patients with obsessive-compulsive disorder (OCD) and generalized anxiety disorder (GAD) do not respond to, or are intolerant of, standard treatments. Additional treatment strategies are therefore necessary. Excessive action of the excitatory neurotransmitter glutamate may play a role in the pathophysiology of OCD and possibly GAD. Memantine blocks the excitatory action of glutamate at the N-methyl- D-aspartate (NMDA) receptor under pathological conditions. The objective of this study was to compare the efficacy and safety of memantine in OCD and GAD, and to probe relative effects on OCD and anxiety symptoms.
|Alternate Journal||Psychopharmacol Bull|